HC Wainwright Reiterates Neutral Rating for Rallybio (NASDAQ:RLYB)

HC Wainwright reaffirmed their neutral rating on shares of Rallybio (NASDAQ:RLYB) in a research note issued to investors on Wednesday, MarketBeat.com reports. HC Wainwright also issued estimates for Rallybio’s Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.97) EPS.

Rallybio Price Performance

RLYB stock opened at $0.25 on Wednesday. Rallybio has a 1-year low of $0.22 and a 1-year high of $2.77. The business has a 50 day simple moving average of $0.64 and a two-hundred day simple moving average of $0.89. The company has a market capitalization of $10.42 million, a price-to-earnings ratio of -0.16 and a beta of -1.35.

Rallybio (NASDAQ:RLYB) last released its earnings results on Thursday, March 13th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.15 million. Sell-side analysts anticipate that Rallybio will post -1.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RLYB. Geode Capital Management LLC lifted its position in shares of Rallybio by 11.4% in the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock worth $287,000 after buying an additional 24,980 shares in the last quarter. FMR LLC grew its holdings in Rallybio by 1.1% during the 3rd quarter. FMR LLC now owns 2,315,480 shares of the company’s stock valued at $2,709,000 after buying an additional 25,422 shares in the last quarter. Northeast Financial Consultants Inc increased its stake in Rallybio by 336.5% in the 4th quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock worth $93,000 after acquiring an additional 74,334 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Rallybio by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock worth $424,000 after acquiring an additional 37,618 shares in the last quarter. Finally, Almitas Capital LLC raised its holdings in shares of Rallybio by 48.3% during the 4th quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock worth $1,246,000 after acquiring an additional 422,685 shares in the last quarter. Institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.